Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Angina IV: Management

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

Heart Failure IV: Classification and Diagnostic Evaluation

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The role of fibrate treatment in dyslipidemia: an overview.

Current pharmaceutical design·2013

Same author

Ezetimibe therapy for dyslipidemia: an update.

Current pharmaceutical design·2013

Same author

Hydrochlorothiazide vs. chlorthalidone as the optimal diuretic for the management of hypertension.

Current pharmaceutical design·2013

Same author

PCSK9 inhibition - a novel mechanism to treat lipid disorders?

Current pharmaceutical design·2013

Same author

Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia?

Current pharmaceutical design·2013

Same author

Achieving current goals in prevention and treatment of vascular disease: an update.

Current pharmaceutical design·2013

Search research articles

Related Experiment Video

Updated: Mar 18, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Lipids, Statins and Heart Failure: An Update.

Niki Katsiki, Michael Doumas, Dimitri P Mikhailidis¹

¹Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital campus University College London Medical School, University College London (UCL) Pond Street, London NW3 2QG, UK. mikhailidis@aol.com.

Current Pharmaceutical Design

|July 12, 2016

Summary

Statins may help prevent heart failure (HF) by improving lipid metabolism and other cardiovascular risk factors. However, their effectiveness in patients with existing HF requires further investigation.

More Related Videos

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Experiment Videos

Last Updated: Mar 18, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Area of Science:

Cardiology
Pharmacology
Metabolic Diseases

Background:

Heart failure (HF) involves cardiac dysfunction and structural changes, influenced by neurohormonal systems and cellular interactions.
Lipid metabolism plays a crucial role in cardiac function and HF development.
Inflammation, oxidative stress, and endothelial dysfunction contribute to HF progression.

Purpose of the Study:

To review the complex relationships between lipids, statin therapy, and heart failure.
To explore the potential benefits of statins in mitigating HF risk factors.
To assess the current understanding of statins' impact on established heart failure.

Main Methods:

Narrative review of existing literature.
Analysis of studies examining lipid metabolism in cardiac function.
Evaluation of evidence on statin pleiotropic effects and cardiovascular risk factor management.

Main Results:

Lipid disorders are implicated in the development and progression of heart failure.
Statins demonstrate potential benefits by influencing lipid metabolism and other cardiovascular risk factors.
Statin therapy may reduce HF incidence through pleiotropic actions on inflammation, oxidative stress, and neurohormonal systems.
Statins can improve associated cardiovascular risk factors like metabolic syndrome and chronic kidney disease.

Conclusions:

Lipid disorders are integral to heart failure pathogenesis.
Statins show promise in managing lipid disorders and related cardiovascular risks in HF.
The efficacy of statins in patients with established heart failure remains uncertain and requires further research.
Specific statin benefits in particular HF patient groups warrant dedicated investigation.